BOCA RATON, FL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced the launch of .dfdv domains in partnership with AllDomains, a universal identity protocol serving over one million users annually. The new top-level domain (TLD) allows individuals, projects, and institutions to register a personalized digital identity ending in .dfdv ...

SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year’s CSCO Meeting, taking place September 10-14 in Jinan, China. Harnessing the Power of Masked CTLA-4 Blockade: Updated ADG126-P001 Phase 1b/2Results of ADG126 + Pembrolizumab in Advanced MSS CRC Presenter: Dr. Xu Ruihu ...

Nasdaq Copenhagen Nikolaj Plads 6DK-1067 Copenhagen K Copenhagen, 5 September 2025ANNOUNCEMENT no. 16/2025 Managers’ transactions Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 5 September 2025. Details of the person discharging managerial responsibilities/person closely associated Name:Jarosław LipińskiReason for the notification: Position/status:CEO in Cemat A/SInitial notification/Amendment:InitialDetails of the issuer, emission allo ...

iFLYTEK AINOTE Air 2 AI-Powered E-Ink Tablet iFLYTEK AINOTE Air 2 AI-Powered E-Ink Tablet FRANKFURT, Germany, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iFLYTEK today announced the launch of its latest E-Ink tablet, AINOTE Air 2, in the European market through joint marketing with Joybuy. With this launch, the Air 2 introduces German and Spanish system interfaces, enabling native users to navigate functions such as transcription and translation more seamlessly. While not yet covering every language in the Germa ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OTTAWA, Ontario, Sept. 05, 2025 (GLOBE NEWSWIRE) -- (TSX: MNT/MNT.U) The Royal Canadian Mint (the “Mint”) announced today that it has completed its previously-announced follow-on offering of 833,200 exchange-traded receipts (“ETRs”) under the Mint’s Canadian Gold Reserves program at a price of C$53.18 per ETR for gross proceeds of C$44,309,576 (the “Offering”). The newly-issued ETRs have been listed on the Toronto Stock ...

Nasdaq Copenhagen Nikolaj Plads 6DK-1067 Copenhagen K Copenhagen, 5 September 2025ANNOUNCEMENT no. 15/2025 Closely related persons transactions Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 5 September 2025. Details of the person discharging managerial responsibilities/person closely associated Name:Peter Tærø NielsenReason for the notification: Position/status:Closely related person to Joanna Lucyna Iwanowska-Nielsen, member of the boar ...

Core Viewpoint - Nukkleus, Inc. has announced a private placement to raise approximately $10 million to fund strategic acquisitions and business expansion initiatives in the Aerospace and Defense sectors [1][2]. Funding Details - The private placement includes a $9.5 million investment from Esousa Group Holdings, LLC and a $500,000 investment from Sixth Borough Capital Fund, LP [1]. - The company will issue 200 units at a price of $50,000 each, consisting of Series A convertible preferred stock and common warrants [2]. Securities Information - Each Series A convertible preferred stock has a stated value of $50,000 and can be converted into 10,224 unregistered shares of common stock at a conversion price of $4.89 per share [2]. - Common warrants allow the purchase of one share of unregistered common stock at an exercise price of $5.405 per share [3]. Acquisition Plans - The net proceeds will be used for acquiring Tiltan Software Engineering Ltd., a defense market AI software provider, and 51% of Star 26 Capital, which owns RIMON, a supplier for the Iron Dome missile defense system [6]. - The company plans to establish advanced manufacturing zones in the Baltics and Israel through a joint venture with Mandragola Ltd. [6]. - Nukkleus aims to commercialize a drone payload license from Blade Ranger Ltd., marking its entry into commercial aviation services [6]. Closing and Regulatory Information - The closing of the private placement is expected around September 9, 2025, pending customary closing conditions [4]. - The securities are being offered in a private placement exempt from registration requirements under the Securities Act of 1933 [5]. Company Overview - Nukkleus focuses on acquiring and scaling suppliers in the defense, aerospace, and advanced manufacturing sectors, targeting Tier 2 and Tier 3 companies [9]. - The company aims to integrate operational capabilities and financial discipline to modernize and expand strategic suppliers, supporting dual-use innovation and resilient supply chains [10].

Core Insights - Imperial Petroleum Inc. reported a fleet expansion, increasing its number of vessels from 12 to 19 during Q2 2025, which is a significant milestone for the company [4][13] - The company experienced a decline in revenues and net income for Q2 2025 compared to Q2 2024, primarily due to decreased tanker market rates [4][31] - Despite the decline in revenues, the company remains profitable and debt-free, holding approximately $212 million in cash as of June 30, 2025 [13][11] Operational Highlights - Fleet operational utilization improved to 83.1% in Q2 2025 from 80.9% in Q2 2024 [4][22] - The fleet's book value increased by 54.4% to slightly above $350 million within a single quarter [4] - The average number of vessels owned increased from 10.3 in Q2 2024 to 14.1 in Q2 2025 [22] Financial Performance - Revenues for Q2 2025 were $36.3 million, a decrease of 22.8% from $47.0 million in Q2 2024 [4][31] - Net income for Q2 2025 was $12.8 million, down from $19.5 million in Q2 2024 [4][31] - For the first half of 2025, the company reported net income of $24.1 million and EBITDA of $31.8 million [4][11] Cash and Debt Position - Cash and cash equivalents, including time deposits, amounted to $212.2 million as of June 30, 2025, which is about 80% higher than the current market capitalization of approximately $120 million [4][11] - The company reported total debt of nil as of June 30, 2025 [11] Market Conditions - Average daily spot rates for product tankers decreased by $9,500, while Suezmax tankers saw an increase of about $1,000 compared to the same period last year [4] - Average daily one-year time charter rates for product and Suezmax tankers were about $12,000 and $18,000 lower, respectively, compared to Q2 2024 [4] Future Outlook - The CEO expressed optimism about the second half of 2025, anticipating favorable market rates for both tankers and drybulk carriers, which could lead to improved financial results [13]

Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advi ...

Core Insights - MAIA Biotechnology, Inc. announced the presentation of ateganosine (THIO) data at the 2025 IASLC World Conference on Lung Cancer, highlighting its potential in treating non-small cell lung cancer (NSCLC) [1][2] - The ongoing THIO-101 trial shows a median overall survival (OS) of 17.8 months, indicating substantial efficacy of ateganosine in late-stage NSCLC patients [3] - The FDA granted Fast Track designation for ateganosine, allowing for expedited regulatory processes and potential accelerated approval [4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with ateganosine as its lead program aimed at treating NSCLC patients with telomerase-positive cancer cells [10] - The company aims to improve and extend the lives of cancer patients through innovative therapies [10] Clinical Trial Details - The THIO-101 Phase 2 clinical trial is designed to evaluate the anti-tumor activity of ateganosine followed by PD-(L)1 inhibitors in advanced NSCLC patients who have shown resistance to previous treatments [9] - The trial has two primary objectives: assessing the safety and tolerability of ateganosine and evaluating its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [9] Conference Information - The IASLC World Conference on Lung Cancer serves as a platform for sharing cutting-edge research and fostering collaboration among industry leaders and experts [6] - MAIA's poster presentation is scheduled for September 7, 2025, focusing on metastatic non-small cell lung cancer and immunotherapy [8]